Clinical and genetic aspects of neurofibromatosis 1
- PMID: 20027112
- DOI: 10.1097/GIM.0b013e3181bf15e3
Clinical and genetic aspects of neurofibromatosis 1
Abstract
Neurofibromatosis 1 is an autosomal dominant disorder characterized by multiple café-au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules. Learning disabilities are present in at least 50% of individuals with neurofibromatosis 1. Less common but potentially more serious manifestations include plexiform neurofibromas, optic nerve and other central nervous system gliomas, malignant peripheral nerve sheath tumors, scoliosis, tibial dysplasia, and vasculopathy. The diagnosis of neurofibromatosis 1 is usually based on clinical findings. Neurofibromatosis 1, one of the most common Mendelian disorders, is caused by heterozygous mutations of the NF1 gene. Almost one half of all affected individuals have de novo mutations. Molecular genetic testing is available clinically but is infrequently needed for diagnosis. Disease management includes referral to specialists for treatment of complications involving the eye, central or peripheral nervous system, cardiovascular system, spine, or long bones. Surgery to remove both benign and malignant tumors or to correct skeletal manifestations is sometimes warranted. Annual physical examination by a physician familiar with the disorder is recommended. Other recommendations include ophthalmologic examinations annually in children and less frequently in adults, regular developmental assessment in children, regular blood pressure monitoring, and magnetic resonance imaging for follow-up of clinically suspected intracranial and other internal tumors.
Similar articles
-
[Neurofibromatosis type 1 or Von Recklinghausen's disease].Rev Med Interne. 2005 Mar;26(3):196-215. doi: 10.1016/j.revmed.2004.06.011. Rev Med Interne. 2005. PMID: 15777582 Review. French.
-
[Neurofibromatosis type 1 and hypertension in pediatrics: case report].Minerva Pediatr. 2011 Aug;63(4):335-9. Minerva Pediatr. 2011. PMID: 21909069 Italian.
-
[Clinical diagnosis of neurofibromatosis type 1].Presse Med. 1999 Dec 11;28(39):2174-80. Presse Med. 1999. PMID: 10629698 French.
-
Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.Postgrad Med. 2019 Sep;131(7):445-452. doi: 10.1080/00325481.2019.1659708. Epub 2019 Sep 12. Postgrad Med. 2019. PMID: 31443616
-
[Neurofibromatosis type 1 - description of clinical features and molecular mechanism of the disease].Med Wieku Rozwoj. 2013 Oct-Dec;17(4):334-40. Med Wieku Rozwoj. 2013. PMID: 24519776 Review. Polish.
Cited by
-
Pulmonary arterial hypertension associated with neurofibromatosis type 1.BMJ Case Rep. 2010 Nov 29;2010:bcr0520102961. doi: 10.1136/bcr.05.2010.2961. BMJ Case Rep. 2010. PMID: 22798089 Free PMC article.
-
Tumors and infections of the growing spine.J Child Orthop. 2023 Nov 24;17(6):556-572. doi: 10.1177/18632521231215857. eCollection 2023 Dec. J Child Orthop. 2023. PMID: 38050596 Free PMC article. Review.
-
Neurofibromatosis type 1 with tarsal conjunctiva thickening: A case report.Medicine (Baltimore). 2019 Aug;98(31):e16699. doi: 10.1097/MD.0000000000016699. Medicine (Baltimore). 2019. PMID: 31374061 Free PMC article.
-
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28. Lancet Oncol. 2019. PMID: 31151904 Free PMC article. Clinical Trial.
-
Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.Vision (Basel). 2024 May 9;8(2):31. doi: 10.3390/vision8020031. Vision (Basel). 2024. PMID: 38804352 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous